53-S (ATCC® HB-8182)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Applications
The antibody cross-reacts with HSV-2 but neutralizes only HSV-1.
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
Spleen cells were fused with P3-NSI/1-Ag4-1 myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against a 110000 dalton glycoprotein on herpes simplex virus type 1 (HSV-1)
Cellular Products
immunoglobulin; monoclonal antibody; against a 110000 dalton glycoprotein on herpes simplex virus type 1 (HSV-1)
Tumorigenic Yes
Effects
Yes, forms ascites in pristane primed BALB/c mice
Comments
Animals were immunized with HSV-1.
Spleen cells were fused with P3-NSI/1-Ag4-1 myeloma cells.
The antibody cross-reacts with HSV-2 but neutralizes only HSV-1.
Complete Growth Medium Iscove's modified Dulbecco's medium, 85%; fetal bovine serum, 15% - OR - RPMI 1640 medium, 85%; fetal bovine serum, 15%
Complete Growth Medium
Culture Medium: Iscove's modified Dulbecco's medium, 85%; fetal bovine serum,
15%.
Subculturing
Medium Renewal: Every 3 to 4 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Isotype IgG2a
Name of Depositor The United States of America
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Showalter SD, et al. Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP 4. Infect. Immun. 34: 684-692, 1981. PubMed: 6277788

Zweig M, et al. Monoclonal antibodies to herpes simplex virus type 1 polypeptides. US Patent 4,572,896 dated Feb 25 1986

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Showalter SD, et al. Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP 4. Infect. Immun. 34: 684-692, 1981. PubMed: 6277788

Zweig M, et al. Monoclonal antibodies to herpes simplex virus type 1 polypeptides. US Patent 4,572,896 dated Feb 25 1986